SRI International is getting involved in drug discovery and research

0



MENLO PARK, Calif., July 07, 2021 (GLOBE NEWSWIRE) – SRI International (SRI) announced today that it has entered into a research partnership with Sanofi. Utilizing SRI’s SynFini â„¢ platform, an artificial intelligence (AI) driven, automated synthetic chemistry system, the collaboration will discover and develop leading candidates in several high-profile drug discovery programs at Sanofi.

SRI’s SynFini platform combines AI and automation to accelerate the discovery and development of small molecules, thereby bringing new drugs to the clinic faster and more cheaply. The platform consists of three components (SynRoute â„¢, SynJet â„¢ and AutoSyn â„¢) that work together seamlessly to automate the design of synthesis routes, reaction screening and optimization (RSO) and the production of target molecules.

“The aim of the SynFini platform is to create a new paradigm in how we approach drug discovery,” said Nathan Collins, chief strategy officer of SRI’s Biosciences Division and director of the SynFini program. “We look forward to working with Sanofi on using our AI-driven automation platform to drive the fast and efficient discovery of therapeutics for high-profile goals.”

The SRI-Sanofi collaboration will also be the recently implemented DASL. from SRITM (Deep Adaptive Semantic Logic) AI-driven molecular design tool for multiparametric optimization in hit-to-lead and lead optimization. Using inferential deep neural networks, DASL efficiently predicts drug designs from the sparse datasets typically available in drug discovery.

About SRI International
SRI International creates world-changing solutions that make people safer, healthier and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in the fields of advanced technologies and systems, life sciences, computers, and education. SRI brings its innovations to market through technology licenses, spin-off ventures and new product solutions.




Share.

Leave A Reply